China Probe Reveals Widespread Drug Data Violations At Major Study Centers
This article was originally published in SRA
Executive Summary
Severe adverse events left unreported, critical data gone missing, subject drugs substituted to pass bioequivalent testing - these are just some of the wrongdoings disclosed by the China Food and Drug Administration in a rare report on regulatory transgressions during drug trials conducted in the country.